- About
- Advertise
- Author Guidelines
- Contact MJH
- Editorial Advisory Board
- Ethics Policy
- Do Not Sell My Personal Information
- LCGC Staff
- Privacy Policy
- Permissions
- Subscriptions
- Terms and Conditions
© 2022 MJH Life Sciences™ and Chromatography Online. All rights reserved.
Pat Sandra | Authors
Articles
Minimizing the Risk of Missing Critical Sample Information by Using 2D-LC
This article explores potential pitfalls associated with 1D‑LC and how 2D‑LC can overcome these obstacles.
Minimizing the Risk of Missing Critical Sample Information by Using Two-Dimensional Liquid Chromatography
Online 2D-LC is a powerful—and accessible—tool for analyzing pharmaceutical and biopharmaceutical samples, in both R&D and QC. It’s now easier than ever to develop 2D-LC methods, and they can be run in a fully automated manner.
Diving into the Structural Details of In Vitro Transcribed mRNA Using Liquid Chromatography–Mass Spectrometry-Based Oligonucleotide Profiling
An overview of mRNA-based vaccine production and a discussion on the methods that are currently in use to check the quality of these vaccines.
High Analytical Performance for Untargeted Aroma Profiling by Combining Dynamic Headspace Sampling, Capillary Gas Chromatography and Time‐of‐Flight Mass Spectrometry
This article looks at the benefits of combining dynamic headspace sampling (DHS) with capillary GC–TOF-MS as a tool for untargeted analysis of aroma compounds in food and beverages. Applications for the analysis of strawberry yoghurt, chocolate, and red wine are described.
Host Cell Protein Monitoring During Downstream Processing Using Micro-Pillar Array Columns Combined with Mass Spectrometry
This article investigates host cell protein analysis using micro-pillar array columns combined with mass spectrometry.
Denaturing and Native Size-Exclusion Chromatography Coupled to High-Resolution Mass Spectrometry for Detailed Characterization of Monoclonal Antibodies and Antibody–Drug Conjugates
Monoclonal antibodies (mAbs) are being developed at an explosive rate and have attracted great interest from both smaller biotech firms and big pharmaceutical companies. Developing mAbs and next-generation antibody–drug conjugates (ADCs) is highly demanding in many ways. From an analytical perspective, handling mAbs and ADCs presents many new challenges. This article describes how size-exclusion chromatography (SEC) combined with high-resolution mass spectrometry (HRMS) can be applied to the detailed characterization of mAbs and ADCs.